These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 11505677

  • 1. Expression of HER2/neu in primary and metastatic breast cancer.
    Tuziak T, Olszewski WP, Olszewski W, Pieńkowski T.
    Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
    [Abstract] [Full Text] [Related]

  • 2. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A, Jouve M, Genin P, Fréneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X.
    Cancer; 2002 Apr 15; 94(8):2169-73. PubMed ID: 12001113
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Apr 15; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C, Schwarz S, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, Brockhoff G.
    J Pathol; 2005 Apr 15; 205(5):577-84. PubMed ID: 15732132
    [Abstract] [Full Text] [Related]

  • 10. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H.
    Mod Pathol; 2002 Feb 15; 15(2):116-24. PubMed ID: 11850540
    [Abstract] [Full Text] [Related]

  • 11. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W, Nofech-Mozes S, Kahn HJ.
    Breast J; 2007 Feb 15; 13(2):122-9. PubMed ID: 17319852
    [Abstract] [Full Text] [Related]

  • 12. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S.
    Rom J Morphol Embryol; 2007 Feb 15; 48(2):121-9. PubMed ID: 17641798
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
    Barnes PJ, Boutilier R, Chiasson D, Rayson D.
    Breast Cancer Res Treat; 2005 May 15; 91(2):173-8. PubMed ID: 15868445
    [Abstract] [Full Text] [Related]

  • 15. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C, von Struensee D, Bierer S, Bögemann M, Hertle L, Eltze E.
    Aktuelle Urol; 2005 Sep 15; 36(5):423-9. PubMed ID: 16163605
    [Abstract] [Full Text] [Related]

  • 16. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y, Booser DJ, Sneige N.
    Cancer; 2005 May 01; 103(9):1763-9. PubMed ID: 15786420
    [Abstract] [Full Text] [Related]

  • 17. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer.
    Stefano R, Agostara B, Calabrò M, Campisi I, Ravazzolo B, Traina A, Miele M, Castagnetta L.
    Ann N Y Acad Sci; 2004 Dec 01; 1028():463-72. PubMed ID: 15650272
    [Abstract] [Full Text] [Related]

  • 18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 19. Absence of HER2 overexpression in metastatic malignant melanoma.
    Inman JL, Kute T, White W, Pettenati M, Levine EA.
    J Surg Oncol; 2003 Oct 01; 84(2):82-8. PubMed ID: 14502781
    [Abstract] [Full Text] [Related]

  • 20. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases.
    Gårdmark T, Wester K, De la Torre M, Carlsson J, Malmström PU.
    BJU Int; 2005 May 01; 95(7):982-6. PubMed ID: 15839918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.